BIAF Key Statistics, Chart & Performance
The current stock price of BIAF is 1.23 USD. In the past month the price decreased by -13.99%. In the past year, price decreased by -95.39%.
BIAF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About BIAF
Company Profile
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Company Info
BIOAFFINITY TECHNOLOGIES INC
3300 Nacogdoches Road, Suite 216
San Antonio TEXAS US
Employees: 57
Phone: 12106985334
BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ
Can you describe the business of BIOAFFINITY TECHNOLOGIES INC?
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
What is the stock price of BIOAFFINITY TECHNOLOGIES INC today?
The current stock price of BIAF is 1.23 USD.
What is the dividend status of BIOAFFINITY TECHNOLOGIES INC?
BIAF does not pay a dividend.
How is the ChartMill rating for BIOAFFINITY TECHNOLOGIES INC?
BIAF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for BIOAFFINITY TECHNOLOGIES INC?
BIOAFFINITY TECHNOLOGIES INC (BIAF) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for BIAF stock?
The Revenue of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to decline by -36.4% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns BIOAFFINITY TECHNOLOGIES INC?
You can find the ownership structure of BIOAFFINITY TECHNOLOGIES INC (BIAF) on the Ownership tab.
BIAF Technical Analysis
BIAF Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIAF. Both the profitability and financial health of BIAF have multiple concerns.
BIAF Financial Highlights
Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -20.94. The EPS increased by 13.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.65% | ||
| ROE | -165.57% | ||
| Debt/Equity | 0.01 |
BIAF Forecast & Estimates
For the next year, analysts expect an EPS growth of 41.46% and a revenue growth -36.4% for BIAF